A recent study demonstrated that liraglutide treatment reversed unconventional cellular defects in WFS1-mutant β-cells, suggesting that repurposing existing diabetes drugs could offer a disease-modifying strategy for this orphan disease [52,53]. Here, WFS1 is linked to diabetes mellitus.